Immunohistochemical features of mammary gland tissue adjacent to the tumor in patients with fibroadenomas

The aim was to study morphological and immunohistochemical features of mammary glands tumor tissue in women with fibroadenomas. Materials and methods. The study used biopsy specimens of mammary gland tissue tumor sites of 58 patients operated on for mammary fibroadenoma. For light-optical examination, the material was fixed in a 10% aqueous solution of neutral formalin and Buen's liquid. After standard histological wiring, the material was poured into paraffin-celloidin. Preparation of serial sections with a thickness of 5-7 micrometers was carried out on a rotational microtome of MPS-2. The dewaxed sections were stained with Mayer's hematoxylin and eosin. The preparations were studied using light microscopy with the Optika B-350 microscope (Optika, Italy) and DCM500 camera. For the immunohistochemical study, antibodies from Thermo Scientific (USA) were used: ER, PR, Ki-67, smooth muscle actin. Results. It was revealed that benign tumors occur on the background of mammary glands benign hyperplasia. In proliferative form of fibro-cystic disease, foci with an excessive content of steroid receptors are formed. Examination of Ki-67 expression allowed to determin the amplification of Ki-67 expression in the tissue in the proliferative form of fibrocystic disease. There was a high expression of smooth muscle actin in non-proliferative and moderate degree of proliferative mastopathy forms. In the case of a proliferative form of fibro-cystic changes of a high degree, the expression of the smooth muscle actin was weaker. Conclusions. High expression of the proliferation marker of Ki-67, estrogen receptor and progesterone in the proliferative form of fibrocystic changes in the tumor tissue is an unfavorable predictor of the disease. Markers that determine the favorable course of the disease are high expression of smooth muscle actin.

молочная железа, пролиферация, рецепторы эстрогена, гладкомышечный актин, mammary gland, proliferation, estrogen receptors, smooth muscle actin

1. Автандилов Г. Г. Медицинская морфометрия. Руководство. М.: Медицина; 1990: 384.

2. Ануфриева С. С. Влияние высокоинтенсивного лазерного излучения на пролиферативную активность эпителиоцитов долек и протоков молочной железы. Современные проблемы науки и образования. 2012; 3. URL: http://www.science-education/ru/103-6143.

3. Байлюк Е. Н. Клинико-морфологические особенности пролиферативных процессов в молочной железе у больных миомой матки. Журнал акушерства и женских болезней. 2010; 59(1): 98-105.

4. Жирнова А. С., Курлаев П. П., Валов С. Д. Морфофункциональная характеристика тканей молочной железы в участках, прилегающих к опухоли, у женщин репродуктивного возраста с диагнозом фиброаденома. Морфология. 2016; 149(3): 82.

5. Костючек И. Н. Морфо-функциональные критерии оценки пролиферативной активности эпителия молочной железы при фиброзно-кистозных изменениях: автореф. дисс. … канд. мед. наук. Санкт-Петербург; 2007: 20.

6. Aupperlee M. D., Haslam S. Z. Differential hormonal regulation and function of progesterone receptor isoforms in normal adult mouse mammary gland. Endocrinology. 2007; 148(5): 2290-2300.

7. Barsky S. H., Karlin N. J. Myoepithelial cells: autocrine and paracrine suppressors of breast cancer progression. Journal of Mammary Gland Biological Neoplasia. 2005; 10(3): 249-260.

8. Carter B. A., Page D. L., Schuyler P. No elevation in long-term breast carcinoma risk for women with fibroadenomas that contain atypical hyperplasia. Cancer. 2001; 92(2): 30-36.

9. Conner P., Skoog L., Soderqvist G. Breast epithelial proliferation in postmenopausal women evaluated through fine-needle-aspiration cytology. Climacteric. 2007; 4(1): 7-12.

10. Coradini D., Daidone M. G. Biomolecular prognostic factors in breast cancer. Current Opinion in Obstetrics & Gynecology. 2004; 16: 49-55.

11. Going J. J., Anderson T. J., Battersby S. Proliferative and secretory activity in human breast during natural and artificial menstrual cycles. American Journal of Pathology. 2008; 130: 193-204.

12. Nieburg H. E. Cancer Prevention & Control Strategy Resolution adopted by the 58th World Health Assembly, Geneva, May 25, 2005. Cancer Detected Prevention. 2005; 29: 403-404.

13. Tse G. M., Tan P. H., Moriya T. The role of immunohistochemistry in the differential diagnosis of papillary lesions of the breast. Journal of Clinical Pathology. 2009; 62(5): 407-413.